Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2217/imt.15.77 http://scihub22266oqcxt.onion/10.2217/imt.15.77 C4976846!4976846!26370838     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Immunotherapy 2015 ; 7 (11): 1187-99 Nephropedia Template TP {{tp|p=26370838|t=2015. Targeting B-cell maturation antigen in multiple myeloma |pdf=|usr=}}{{26370838}} gab.com Text Targeting B-cell maturation antigen in multiple myeloma JO: Immunotherapy http://www.kidney.de/pget.php?&tw=1&pmid=26370838 #FOAvip Novel effective immunotherapies are needed for patients with multiple myeloma (MM), since disease recurrence remains a major obstacle. B-cell maturation antigen (BCMA), a cell surface protein universally expressed on malignant plasma cells , has emerged as a very selective antigen to be targeted in novel treatments for MM. We here first review BCMA-related biology, and then highlight the recent clinical development of a novel afucosylated anti-BCMA monoclonal antibody conjugated with monomethyl auristatin F via noncleavable linker (GSK2857916). Chimeric antigen receptor-expressing T cells targeting BCMA may also induce specific and durable anti-MM responses by patients? own effector cells. Clinical trials testing these two approaches (NCT02064387, NCT02215967) are currently ongoing in relapsed and refractory MM patients. Twit Text FOAVip Targeting B-cell maturation antigen in multiple myeloma ????Immunotherapy http://www.kidney.de/pget.php?&tw=1&pmid=26370838 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26370838 #FOAvip English Wikipedia <ref>{{Cite pmid|26370838}}</ref> Targeting B-cell maturation antigen in multiple myeloma #MMPMID26370838 Tai YT; Anderson KC Immunotherapy 2015[Nov]; 7 (11): 1187-99 PMID26370838show ga Novel effective immunotherapies are needed for patients with multiple myeloma (MM), since disease recurrence remains a major obstacle. B-cell maturation antigen (BCMA), a cell surface protein universally expressed on malignant plasma cells , has emerged as a very selective antigen to be targeted in novel treatments for MM. We here first review BCMA-related biology, and then highlight the recent clinical development of a novel afucosylated anti-BCMA monoclonal antibody conjugated with monomethyl auristatin F via noncleavable linker (GSK2857916). Chimeric antigen receptor-expressing T cells targeting BCMA may also induce specific and durable anti-MM responses by patients? own effector cells. Clinical trials testing these two approaches (NCT02064387, NCT02215967) are currently ongoing in relapsed and refractory MM patients. äTargeting B-cell maturation antigen in multiple myeloma (epmc).pdf DeepDyve Pubget Overpricing